UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No. 1900.0430002/JMC/MBT First Inventor SALZWEDEL et al. Inhibition of HIV-1 Replication by Disruption of Title the Processing of the Viral Capsid-Spacer Peptide 1 Protein

(Only for new nonprovisional applications under 37 CFR 1.53(b))

			Express ivial	Lubor No.				
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.			ADDRESS	ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450			PT0 28	
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. 3. Specification [Total Pages 7.3] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention			Col 8. Nucleot	7. CDiROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF)				
			i. ii.	i. CD-ROM or CD-R (2 copies); or ii. Paper				
- Brief Description of the Drawings (if filed)			с. 🗀	c. Statements verifying identity of above copies				
- Detailed Description				ACCOMPANYING APPLICATION PARTS				
- Claim(s) - Abstract	70	ACCUMITATING APPLICATION PARTS						
4. X Drawing(s) (35 U.S.C. 113) [Total Sheets] 5. Oath or Declaration [Total Sheets]			10.	10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11. English Translation Document (if applicable)				
a. Newly executed (original or copy)				nformation Discl		Copies of II	os .	
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)			13. L P	14. X Return Receipt Postcard (MPEP 503)				
i. DELETION OF INVENTOR(S)				(Should be specifically itemized)				
Signed statement attached deleting inventor(s)				15. Certified Copy of Priority Document(s) (if foreign priority is claimed)				
name in the prior application, see 37 CFR								
1.63(d)(2) and 1.33(b).			(i	(b)(2)(B)(i). Applicant must attach form PTO/SB/35				
6. X Application Data Sheet. See 37 CFR 1.76				or its equivalent. Other: Authorization under 37CFR 1.136(a)(3) The name of the assignee is:				
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:								
Continuation Divisional Continuation-in-part (CIP) of prior application No.:								
Prior application information: Examiner For CONTINUATION OF DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
19. CORRESPONDENCE ADDRESS								
						ce address belov	v	
Name Sterne, Kessler, Goldstein & Fox P.L.L.C.								
Address	2.5, 2.5							
City		State	State		Zip Code			
Country	Te		Telephone		F	эх		
Name (Print/Type) Mary B. Tung Registration No. (Attorney/Agent) 50,007								
Signature Mann B Diny					Date	gan. 29, 2	004	

This collection of information is required by 37 CFR 1.53(b) The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Kimberly N. Reddick

Theodore A. Wood Elizabeth J. Haanes Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershender Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser
Daniel A. Klein*
Rodney G. Maze
Jason D. Eisenberg
Michael D. Specht
Andrea J. Karnage
Tracy L. Muller*
Jon E. Wright* LuAnne M. Yuricek*

John J. Figueroa Ann E. Summerfield Registered Patent Agents Karen R. Markowicz Nancy J. Leith Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Mary B. Tung Katrina Y. Pei Bryan L. Skelton

Robert A. Schwartzman Timothy A. Doyle Jennifer R. Mahalingappa

Mail Stop Patent Application

Teresa A. Colella

Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes

Of Counsel Kenneth C. Bass III Evan R. Smith

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

January 29, 2004

WRITER'S DIRECT NUMBER: (202) 772-8840 **INTERNET ADDRESS:** MTUNG@SKGF.COM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be assigned; Filed: January 29, 2004

Inhibition of HIV-1 Replication by Disruption of the Processing of the

Viral Capsid-Spacer Peptide 1 Protein

Inventors:

SALZWEDEL et al.

Our Ref:

1900.0430002/JMC/MBT

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. USPTO Utility Patent Application Transmittal Form PTO/SB/05;
- 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating 2. An Extension of Time;
- U.S. Utility Patent Application entitled:

Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein

and naming as inventors:

Karl SALZWEDEL Feng LI Carl T. WILD Graham P. ALLAWAY Eric O. FREED

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents January 29, 2004 Page 2

the application comprising:

- a. an Application Data Sheet (37 C.F.R. § 1.76);
- b. specification containing:
 - i. 60 pages of description prior to the claims;
 - ii. 12 pages of claims (81 claims);
 - iii. a one (1) page abstract;
- c. 11 sheets of drawings: (Figures 1-10); and
- 4. Two (2) return postcards.

Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

Mary B. Jung

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mary B. Tung

Agent for Applicants

Registration No. 50,007

JMC/MBT/lam Enclosures

224030.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SALZWEDEL et al.

Appl. No.: To be assigned

Filed: January 29, 2004

For: Inhibition of HIV-1 Replication by Disruption of the Processing of the

Viral Capsid-Spacer Peptide 1

Protein

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 1900.0430002/JMC/MBT

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mary B. Tung

Agent for Applicants

Registration No. 50,007

Date: <u>January 29, 2004</u> 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600